07:16 AM EDT, 09/02/2025 (MT Newswires) -- Merck & Co ( MRK ) said Tuesday its investigational oral PCSK9 inhibitor enlicitide decanoate met all primary and key secondary endpoints in adults with hypercholesterolemia in CORALreef lipids study.

The company said that the treatment with enlicitide resulted in statistically significant and clinically meaningful reduction in low-density lipoprotein cholesterol compared with placebo at week 24.

The company also said statistically and clinically significant reductions were also seen for enlicitide versus placebo across all key secondary endpoints, including in non-high-density lipoprotein cholesterol, apolipoprotein B and lipoprotein.

Merck ( MRK ) said there were no clinically meaningful differences in proportions of participants with adverse events, including serious adverse events, between treatment groups and discontinuations due to adverse events were low and comparable between treatment groups.